I need to read through this 10-Q filing carefully to extract key financial and operational facts before writing the article. The filing is a 10-Q for Rapport Therapeutics, Inc. for the quarterly period ended September 30, 2026, filed on November 4, 2026. The ticker is RAPP on the Nasdaq Global Market. Key facts I can confirm from the filing text provided: - Company: Rapport Therapeutics, Inc. - Filing type: 10-Q - Period: quarterly period ended September 30, 2026 - Exchange/ticker: RAPP on The Nasdaq Global Market (so NASDAQ:RAPP) - Shares outstanding as of November 2, 2026: 59,279,630 - Commission File Number: 001-42121 - State of incorporation: Delaware - EIN: 88-0724208 - Address: 99 High Street, Suite 2100, Boston, MA 02110 - Classification: Non-accelerated filer, Smaller reporting company, Emerging growth company - Did not elect extended transition period for accounting standards - Not a shell company - Clinical-stage biotechnology company - Has incurred significant financial losses since inception - Will require additional funding - Has license agreement with Tenacia Biotechnology (Hong Kong) Co., Ltd. - Has intellectual property licenses with Janssen Pharmaceutical NV - Has outstanding indebtedness (mentioned in forward-looking statements) - RAP technology platform The filing content provided is mostly the cover page, table of contents, and forward-looking statements section. The actual financial statements (balance sheets, income statements, cash flows) are referenced but not included in the extracted text. I cannot state specific financial figures I cannot confirm from the text. Let me write the article with only what I can confirm.

Rapport Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 4, 2026, disclosing its financial position and operational status as a clinical-stage biotechnology company.

Key Highlights

  • Shares outstanding: As of November 2, 2026, the registrant had 59,279,630 shares of common stock, $0.001 par value per share, outstanding.
  • Clinical-stage company: The company disclosed it is "a clinical-stage biotechnology company with a limited operating history" and has "incurred significant financial losses since our inception."
  • Additional funding needed: According to the filing, the company "will require additional funding in order to finance operations."
  • Key license relationships: The filing identifies intellectual property licenses with Janssen Pharmaceutical NV and a license agreement with Tenacia Biotechnology (Hong Kong) Co., Ltd. as material to operations.
  • Filer classification: Rapport Therapeutics is classified as a non-accelerated filer, smaller reporting company, and emerging growth company under SEC definitions.
  • Outstanding indebtedness: The filing lists "the Company's outstanding indebtedness" among the factors subject to its forward-looking statement cautionary language.

Rapport Therapeutics Q3 2026 Quarterly Disclosure: Clinical Stage Operations and Funding Needs

Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company headquartered at 99 High Street, Suite 2100, Boston, MA 02110, submitted its Form 10-Q for the quarterly period ended September 30, 2026, to the SEC on November 4, 2026. The filing carries Commission File Number 001-42121 and was submitted under Delaware incorporation with IRS Employer Identification Number 88-0724208.

As of November 2, 2026, the registrant reported 59,279,630 shares of common stock outstanding at a par value of $0.001 per share. The company confirmed that it has filed all required reports under the Securities Exchange Act during the preceding 12 months and has submitted all required Interactive Data Files electronically. The company did not elect to use the extended transition period for complying with new or revised financial accounting standards, as indicated on the cover page of the filing.

The filing's summary risk factors section states that Rapport Therapeutics "will require additional funding in order to finance operations" and that if it is "unable to raise capital when needed, or on acceptable terms," it "could be forced to delay, reduce or eliminate" its programs. The company also disclosed outstanding indebtedness as a factor affecting its forward-looking statements. Its RAP technology platform and existing license arrangements, including those with Janssen Pharmaceutical NV and Tenacia Biotechnology (Hong Kong) Co., Ltd., are cited among the key areas of operational focus. All forward-looking statements in the filing are subject to the company's cautionary language and the risk factors described within the quarterly report.

What Was Disclosed

Rapport Therapeutics filed a quarterly report covering the period ended September 30, 2026, disclosing 59,279,630 shares outstanding as of November 2, 2026, its clinical-stage status, continued financial losses, need for additional funding, and outstanding indebtedness, along with key license relationships.